Iovance Biotherapeutics Inc
$ 3.82
4.95%
15 Apr - close price
- Market Cap 1,499,540,000 USD
- Current Price $ 3.82
- High / Low $ 3.83 / 3.53
- Stock P/E N/A
- Book Value 1.70
- EPS -1.09
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.56 %
- 52 Week High 5.63
- 52 Week Low 1.64
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Analyst Target Price
$9.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.5 |
| Estimated EPS | -0.1764 | -0.2617 | -0.28 | -0.42 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.45 | -0.8 | -0.74 |
| Surprise | -0.0036 | 0.0117 | -0.05 | 0.06 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | -0.01 | 0.33 | 0.24 |
| Surprise Percentage | -2.0408% | 4.4708% | -17.8571% | 14.2857% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | -2.2222% | 41.25% | 32.4324% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2026-04-11 16:09:06
Iovance Biotherapeutics (IOVA) has seen its stock underperform despite the 2024 approval of its advanced melanoma treatment, Amtagvi, which generated $263.5 million in sales last year and is projected to reach over $1 billion annually by 2030. The company is also expanding the therapy's indications, but faces risks typical of small drug developers, including potential clinical setbacks and the complex logistical challenges of its tumor-infiltrating lymphocyte therapies.
2026-04-11 11:39:47
Iovance Biotherapeutics (IOVA) has seen its stock rise following promising real-world data for its therapy, Amtagvi, in advanced melanoma, showing higher response and disease control rates than its pivotal trial. This improved efficacy data, coupled with advancing clinical trials in other cancers like non-small cell lung cancer, is strengthening hopes for Amtagvi to become a foundational treatment across various solid tumors. Despite the positive data, investors are advised to consider risks such as pricing pressure, potential regulatory setbacks, and the company's current cash runway.
2026-04-11 04:39:19
This article provides a fundamental analysis of IOVANCE BIOTHERAPEUTICS INC (IOVA), assigning it an overall fundamental rating of 2 out of 10. The company faces challenges with negative profitability and a rather negative financial health evaluation, leading to a valuation that is considered quite expensive despite a decent growth rate. Future projections indicate strong expected growth in Earnings Per Share and Revenue in the coming years.
2026-04-11 03:39:47
Iovance Biotherapeutics (IOVA) experienced a stock decline of nearly 9% despite significant sales growth for its melanoma treatment, Amtagvi, and positive early results for a new drug. The company faces ongoing clinical and regulatory risks in the biotech sector, leading to investor caution. Analysts, however, generally maintain a "Buy" rating with optimistic price targets, particularly following a competitor's drug rejection which is seen to strengthen Amtagvi's market position.
2026-04-10 18:39:07
Chardan Capital has reiterated its Buy rating for Iovance Biotherapeutics (IOVA.US) and maintained its target price at $16. This indicates the firm's continued confidence in the company's prospects.
2026-04-10 16:04:11
Iovance Biotherapeutics Inc. (IOVA) stock is experiencing a downward trend of -7.23% following investor anxiety about its clinical trial outlook. Despite significant quarterly revenue of $86.8 million, the company faces substantial losses and high operating cash burn. Traders are closely monitoring key support at $3.30 and resistance between $4.00 and $4.30, with the stock exhibiting textbook consolidation patterns, making it a speculative but technically interesting play.
